Acknowledgments The authors take great pleasure in thanking the staff of Flanders Medical Research Program (www.fmrp.be), in particular Koen De Meester, who performed the systematic review of the literature and provided substantial support dur- ing the writing of the article. The authors report no conﬂicts of interest. References Abou-Chebl A, Bashir Q, Yadav JS. 2005. Drug-eluting stents for the treat- ment of intracranial atherosclerosis: initial experience and midterm angiographic follow-up. Stroke, 36:165–8. Bosiers M, Deloose K, Verbist J, et al. 2006. Percutaneous transluminal angioplasty for treatment of “below-the-knee” critical limb ischemia: early outcomes following the use of sirolimus-eluting stents. J Cardio- vasc Surg(Torino), 47:171–6. Bosiers M, Deloose K, Verbist J, et al. 2007. Nitinol stenting for treatment of ‘below-the-knee’ critical limb ischemia: 1 year angiographic outcome of the Xpert stent. J Cardiovasc Surg(Torino), 48:455–61. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. 2005. Warfarin-aspirin symptomatic intracranial disease trial investigators: comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med, 352:1305–16. Commeau P, Barragan P, Roquebert PO. 2006. Sirolimus for below the knee lesions: mid-term results of SiroBTK study. Catheter Cardiovasc Interv, 68:793–8. Diener HC, Bogousslavsky J, Brass LM, et al.; MATCH Investigators. 2004. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 364:331–7. Duda SH, Pusich B, Richter G, et al. 2002. Sirolimus-eluting stents for the treatment of obstructive superﬁcial femoral artery disease: Six-month results. Circulation, 106:1505–9. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superﬁcial femoral artery disease: The SIROCCO II trial. J Vasc Interv Radiol, 16:331–8. Duda SH, Bosiers M, Lammer J, et al. 2006. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superﬁcial femoral artery: Long-term results from the SIROCCO trial. J Endovasc Ther, 13:701–10. Eisenstein EL, Anstrom KJ, Kong DF, et al. 2007. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA, 297:159–68. Feiring AJ, Wesolowski AA, Lade S. 2004. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. J Am Coll Cardiol, 44:2307–14. Feiring AJ, Wesolowski AA. 2007. Antegrade popliteal artery approach for the treatment of critical limb ischemia in patients with occluded superficial femoral arteries. Catheter Cardiovasc Intervi, 69:665-70. Granillo GA, van Dijk LC, McFadden EP, et al. 2005. Percutaneous radial intervention for complex bilateral renal artery stenosis using paclitaxel eluting stents. Catheter Cardiovasc Interv, 64:23–7. Gupta R, Al-Ali F, Thomas AJ, et al. 2006. Safety, feasibility, and short- term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke, 37:2562–6. Harper RW. 2007. Drug-eluting stents coronary stents - a note of caution. Med J Aust, 186:253–5. Hill R, Bagust A, Bakhai A, et al. 2004. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess, 8(35):iii-iv, 1–242. Vascular Health and Risk Management 2008:4(3) DES in the management of PAD Holmes DR, Leon MB, Moses JW, et al. 2004. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary reste- nosis. Circulation, 109:634–40. Kakkar AK, Fischi M, Narins CR. 2006. Drug-eluting stent implantation for treatment of recurrent renal artery in-stent restenosis. Catheter Cardiovasc Interv, 68:118–22; discussion 123–4. Kasner SE, Chimowitz MI, Lynn MJ, et al. 2006. Warfarin Aspirin symp- tomatic intracranial disease trial. Circulation, 113:555–63. Ko Y-G, Park S, Kim J-Y, et al. 2004. Percutaneous interventional treatment of extracranial vertebral artery stenosis with coronary stents. Yonsei Med J, 45:629–34. Levy EI, Hanel RA, Howington JU, et al. 2004. Sirolimus-eluting stents in the canine cerebral vasculature: a prospective, randomized, blinded assessment of safety and vessel response. J Neurosurg, 100:688–94. Mauri L, Orav EJ, Candia SC, et al. 2005. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation, 112:2833–9. Moreno R, Fernandez C, Hernandez R, et al. 2005. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol, 45:954–9. Norgren L, Hiatt WR, Dormandy JA, et al. 2007. TASC II working group. Intersociety consensus for the mangement of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg, 33(Suppl 1):S1–75. Nussbaumer-Ochsner Y, Eberli FR, Baumgartner RW, et al. 2006. Sirolimus-eluting stenting of the external carotid artery for the treatment of ocular ischemia. J Endovasc Ther, 13:672–5. Qureshi AI, Kirmani JF, Hussein HM, et al. 2006. Early and intermedi- ate-term outcomes with drug-eluting stents in high-risk patients with symptomatic intracranial stenosis. Neurosurgery, 59:1044–51. Roiron C, Sanchez P, Bouzamondo A, et al. 2006. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart, 92:641–9. Sapoval M, Zahringer M, Pattynama P, et al. 2005. Low-proﬁle stent system for treatment of atherosclerotic renal artery stenosis: The GREAT trial. J Vasc Interv Radiol, 16:1195–202. Scheinert D, Ulrich M, Scheinert S, et al. 2006. Comparison of sirolimus- eluting vs. bare-metal stents for the treatment of infrapopliteal obstruc- tions. EuroInterv, 2:169–74. Schwarzmaier-D’Assie A, Karnik R, et al. 2007. Fracture of a drug- eluting stent in the tibioperoneal trunk following bifurcation stenting. J Endovasc Ther, 14:106–9. Siablis D, Kraniotis P, Karnabatidis D, et al. 2005. Sirolimus-eluting versus bare stents for bailout after suboptimal infrapopliteal angioplasty for critical limb ischemia: 6-month angiographic results from a nonrandom- ized prospective single-center study. J Endovasc Ther, 12:685–95. Siablis D, Karnabatidis D, Katsanos K, et al. 2007. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical beneﬁt. J Endovasc Ther, 14:241–50. Stone GW, Ellis SG, Cox DA, et al. 2004. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation, 109:1942–7. SSYLVIA Investigators. 2004. Stenting of symptomatic atherosclerotic lesions in the vertebral or intracranial arteries (SSYLVIA): study results. Stroke, 35:1388–92. Waksman R. 2006. Update on bioabsorbable stents: From bench to clinical. J Interven Cardiol, 19:414–21. Zähringer M, Sapoval M, Pattynama PMT, et al. 2007. Sirolimus-elutinG versus bare-metal low-profile stent for REnal Artery Treatment (GREAT trial): Angiographic follow-up after 6 month and clinical outcome up to 2 years. J Endovasc Ther, 14:460–8. Zeller T, Rastan A, Rothenpieler U, et al. 2006. Restenosis after stenting of atherosclerotic renal artery stenosis: Is there a rationale for the use of drug-eluting stents? Catheter Cardiovasc Interv, 68:125–30. 559